The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
Adam Mecca, MD, PhD
Advertisement
Associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine
Articles by Adam Mecca, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
2
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
3
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
4
This Week on NeurologyLive® — November 3, 2025
5
